Last updated: 2026-11-13 16:14:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
NervGen Pharma Corp. (NGEN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.91, with a market capitalization of $175.26M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.28 to $6.30. This page covers its latest market performance, valuation, price trends and company information.
$175.26M | |
$1.68 | |
$1.91 | |
$1.53 | |
$1.63 | |
863.83K | |
534.89K | |
-- | |
$6.30 | |
$1.28 | |
-- | |
-- |
NervGen Pharma Corp. (NGEN) is currently trading at $1.91 as of 2026-11-13 16:13:00, up 13.19% ($0.22) from the previous close of $1.63
During today's regular trading session, NGEN has traded between $1.53 and $1.91, with a trading volume of 863.83K shares. The current price is near the upper end of today's range.
Over the past seven days, NervGen Pharma Corp. (NGEN) moved from $1.32 to $1.91, representing a gain of 44.62% ($0.59).
The stock traded between $1.29 and $1.91 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 614.21 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 12.5%
NGEN is currently trading at $1.91, placing it 12.5% of the way from its 52-week low of $1.28 to its 52-week high of $6.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
| Employees | 9 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to NervGen Pharma Corp. and NGEN stock.
Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI studyPhase 3 RESTORE registrational study enrolling participants, with
Eligible investors can buy real shares of NervGen Pharma Corp. (NGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NGEN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NGEN shares and USD.
NGEN Shares to USD
1.00 NGEN shares = 1.909 USD
Calculations are estimates based on the latest available price and are for reference only.
